Aileron Therapeutics Inc.
Aileron Therapeutics Inc. is listed today as Rein Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2023 | $18 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| Dec 2016 | $30 M | No. 4 | $10 to $50 million | equity | SEC | |
| Oct 2014 | $20 M | No. 3 | $10 to $50 million | equity | SEC | |
| Nov 2013 | $15 M | No. 2 | $10 to $50 million | equity | SEC | |
| May 2009 | $28 M | No. 1 | $10 to $50 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Aileron Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2023).
SEC Form D · Nov 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2023
Products and services#
No products or services of Aileron Therapeutics Inc. are on record.
Investors#
18 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| AJU IB Investment Co., Ltd. | Fund or asset manager | not stated | not stated | Held Series E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Apple Tree Partners II - Annex, L.P. | Fund or asset manager | not stated | not stated | Held Series E and E-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Apple Tree Partners II LP | Fund or asset manager | not stated | not stated | Held Series A, A-1, B, C, C-2 and D preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| CVF LLC | Other | not stated | not stated | Held Series E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Excel Medical Fund LP | Fund or asset manager | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Excel Medical Ventures, LLC | Venture capital | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| James Brian Windsor | Person | not stated | not stated | Held Series X preferred stock (Form 3, 2023) | SEC Form 3 |
| Jon B. Platt | Person | not stated | not stated | Held Series C-2, D, E and E-1 preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| KCK LTD. | Company | not stated | not stated | Held Series E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Lilly Ventures Fund I LLC | Venture capital | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| LV Management Group, LLC | Fund or asset manager | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Novartis AG | Company | not stated | not stated | Held Series C, C-2, D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Novartis Bioventures Ltd | Venture capital | not stated | not stated | Held Series C, C-2, D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Roche Finance LTD | Company | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Roche Holding LTD | Company | not stated | not stated | Held Series D, E-2, E-3 and F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Scott Kapnick | Person | not stated | not stated | Held Series D, D-1, E-2, E-3 and F preferred (Form 3, 2017) | SEC Form 3 |
| Sigma Emerging Markets Ltd. | Company | not stated | not stated | Held Series F preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Largest shareholders today
Institutions holding Rein Therapeutics, Inc. shares, as of Sep 30, 2026.
- Voss Capital, LP$5 M6.78%
- Cable Car Capital, LP$4 M6.02%
- ADAR1 Capital Management, LLC$4 M5.22%
- Vanguard Capital Management LLC$3 M3.89%
- BIOS Capital Management, LP$2 M3.46%
- Ikarian Capital, LLC$2 M3.42%
- Citadel Advisors LLC$2 M2.98%
- Velan Capital Investment Management LP$1 M1.97%
- Great Point Partners LLC$1 M1.93%
- Prosight Management, LP$1 M1.92%
- Senvest Management, LLC$1 M1.43%
- Bleichroeder LP$1 M1.16%
- Boothbay Fund Management, LLC$1 M1.03%
- Geode Capital Management, LLC$1 M0.97%
- University Of Texas/texas Am Investment Management Co$0 M0.59%
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brian L. Windsor, Ph.D. | Executive officer | Nov 2023 |
| Manuel Alves-Aivado, M.D., Ph.D. | Executive officer | Nov 2023 |
| Susan L. Drexler | Executive officer | Nov 2023 |
| Joseph A. Yanchik III | Executive officer | Jan 2017 |
| Manuel H. Aivado | Executive officer | Jan 2017 |
| Alan H. Musso | Director | Nov 2023 |
| Josef H. von Rickenbach | Director | Nov 2023 |
| Manuel Alves-Aivado, M.D., Ph.D. | Director | Nov 2023 |
| Nolan H. Sigal, M.D., Ph.D. | Director | Nov 2023 |
| Reinhard J. Ambros | Director | Nov 2023 |
| William H. Fairey | Director | Nov 2023 |
| Armen H. Shanafelt | Director | Jan 2017 |
| Brian M. Gallagher, Jr. | Director | Jan 2017 |
| Caleb H. Winder | Director | Jan 2017 |
| John H. McArthur | Director | Jan 2017 |
| Joseph A. Yanchik III | Director | Jan 2017 |
| Scott L. Kapnick | Director | Jan 2017 |
| Seth L. Harrison | Director | Jan 2017 |
| Enrico H. Petrillo | Director | Oct 2014 |
| Campbell Murray | Director | Jun 2009 |
| Enrico Petrillo | Director | Jun 2009 |
| Michael Diem | Director | Jun 2009 |
| Seth Harrison | Director | Jun 2009 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.